Matthew W Martin

USPTO Granted Patents = 73 (Patent Applications = 21)

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 15 (Patent Applications = 15)

Average Co-Inventor Count = 8.9

ph-index = 14

Forward Citations = 599(Granted Patents)

Forward Citations (Not Self Cited) = 322(Oct 12, 2025)

Inventors with similar research interests:

Location History:

Cambridge, MA (US) (2008 - 2010)
Arlington, MA (US) (2010 - 2024)

Company Filing History:

50 out of 125

Forma Therapeutics, Inc.

Valo Early Discovery, Inc.

patents

5. 1 out of 290

H. Lee Moffitt Cancer Center and Research Institute, Inc.

patents

where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...

73 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12264137 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2025-04-01),

2. 12049466 - Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors (2024-07-30),

3. 11919839 - Alpha-cinnamide compounds and compositions as HDAC8 inhibitors (2024-03-05),

4. 11891365 - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2024-02-06),

5. 11814386 - Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors (2023-11-14),

6. 11535618 - Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors (2022-12-27),

7. 11535607 - Isoindolines as HDAC inhibitors (2022-12-27),

8. 11345672 - Methods using HDAC11 inhibitors (2022-05-31),

9. 11299484 - Inhibiting fatty acid synthase (FASN) (2022-04-12),

10. 11279681 - 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2022-03-22),

11. 11274085 - 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2022-03-15),

12. 11274084 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2022-03-15),

13. 11267805 - Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone (2022-03-08),

14. 11247987 - Inhibiting ubiquitin specific peptidase 30 (2022-02-15),

15. 11111229 - Tetrahydroquinoline compositions as BET bromodomain inhibitors (2021-09-07),

Title: Matthew W Martin: A Trailblazing Inventor in the Field of Technology

Introduction:

Matthew W Martin, a visionary inventor based in Arlington, MA (US), is recognized for his exceptional passion for innovation and relentless pursuit of excellence in the field of technology. With an impressive track record of 71 patents to his name, Martin's contributions have not only made a mark in the industry but also continue to inspire future generations of inventors and innovators.

Latest Patents:

1. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors: This patent focuses on inhibitors of histone deacetylases, specifically HDAC8, which have shown promise in the treatment of cancer and various diseases. The synthesis and applications of these inhibitors mark a significant advancement in medical research.

2. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors: This patent explores inhibitors of zinc-dependent histone deacetylases (HDACs) that are effective in treating diseases associated with HDAC6. The chemical formula described in the patent opens new possibilities for therapeutic interventions.

Career Highlights:

Matthew W Martin has made substantial contributions to the technology sector through his work with prominent companies such as Forma Therapeutics, Inc. and Amgen Inc.. His innovative ideas and groundbreaking research have led to the development of novel solutions that address critical challenges in the industry.

Collaborations:

Throughout his career, Martin has collaborated closely with esteemed professionals in the field, including David R Lancia, Jr and David S Millan. These collaborative efforts have resulted in the successful execution of innovative projects and the creation of cutting-edge technologies.

Conclusion:

In conclusion, Matthew W Martin's dedication to innovation and his exceptional talent as an inventor have established him as a trailblazer in the technology landscape. His groundbreaking patents and collaborative endeavors underscore his commitment to advancing the field and shaping the future of technology. Matthew W Martin's legacy as a visionary inventor continues to inspire and drive progress in the realm of inventions and innovations.

This text is generated by artificial intelligence and may not be accurate.